1. Home
  2. HALO vs KNX Comparison

HALO vs KNX Comparison

Compare HALO & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • KNX
  • Stock Information
  • Founded
  • HALO 1998
  • KNX 1989
  • Country
  • HALO United States
  • KNX United States
  • Employees
  • HALO N/A
  • KNX N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • KNX Trucking Freight/Courier Services
  • Sector
  • HALO Health Care
  • KNX Industrials
  • Exchange
  • HALO Nasdaq
  • KNX Nasdaq
  • Market Cap
  • HALO 7.4B
  • KNX 7.2B
  • IPO Year
  • HALO N/A
  • KNX 1994
  • Fundamental
  • Price
  • HALO $58.79
  • KNX $39.39
  • Analyst Decision
  • HALO Buy
  • KNX Buy
  • Analyst Count
  • HALO 9
  • KNX 19
  • Target Price
  • HALO $61.63
  • KNX $55.83
  • AVG Volume (30 Days)
  • HALO 1.8M
  • KNX 3.4M
  • Earning Date
  • HALO 05-06-2025
  • KNX 04-23-2025
  • Dividend Yield
  • HALO N/A
  • KNX 1.83%
  • EPS Growth
  • HALO 63.33
  • KNX N/A
  • EPS
  • HALO 3.43
  • KNX 0.73
  • Revenue
  • HALO $1,015,324,000.00
  • KNX $7,410,078,000.00
  • Revenue This Year
  • HALO $20.06
  • KNX $5.19
  • Revenue Next Year
  • HALO $24.04
  • KNX $8.17
  • P/E Ratio
  • HALO $17.14
  • KNX $54.16
  • Revenue Growth
  • HALO 22.44
  • KNX 3.76
  • 52 Week Low
  • HALO $37.73
  • KNX $36.69
  • 52 Week High
  • HALO $66.00
  • KNX $61.51
  • Technical
  • Relative Strength Index (RSI)
  • HALO 44.06
  • KNX 38.13
  • Support Level
  • HALO $57.50
  • KNX $37.70
  • Resistance Level
  • HALO $62.14
  • KNX $40.80
  • Average True Range (ATR)
  • HALO 2.90
  • KNX 2.49
  • MACD
  • HALO -0.40
  • KNX 0.02
  • Stochastic Oscillator
  • HALO 36.41
  • KNX 31.00

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the U.S. Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: